Evofem Biosciences Inc expected to post a loss of 29 cents a share - Earnings Preview

Evofem Biosciences

12/11/2021 13:23

* Evofem Biosciences Inc  EVFM.OQ   EVFM.O  is expected to show
a rise in quarterly revenue when it reports  results on November
15. 
* The San Diego, California-based company is expected to report 
a 1,118.6% increase in revenue to $3.388 million from $278
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Evofem Biosciences Inc
is for a loss of 29 cents per share. For the same quarter last
year, the company reported a loss of 37 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Evofem
Biosciences Inc is $3.25​, about 79.7% above​ its last closing
price of $0.66. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  -0.37       -0.37      -0.27     Beat    26.5
 Mar. 31 2021  -0.49       -0.49      -0.56     Missed  -14.9
 Dec. 31 2020  -0.40       -0.36      -0.50     Missed  -37.9​
 Sep. 30 2020  -0.44       -0.44      -0.37     Beat    15.9
 ​​Jun.        -0.37       -0.37      -0.91     Missed  -143.8
 30 2020                                                
 Mar. 31 2020  -0.33       -0.32      -0.40     Missed  -25​
 Dec. 31 2019  -0.28       -0.29      -0.27     Beat    6.3
 Sep. 30 2019  -0.31       -0.31      -0.30     Beat    3.8
 This summary was machine generated November 12 at 13:23 GMT. 
All figures in US dollars  unless otherwise stated